Exelixis (EXEL) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Exelixis (NASDAQ: EXEL):

• 7/14/2026 – Exelixis had its price target raised by Barclays PLC from $45.00 to $49.00. They now have an “equal weight” rating on the stock.
• 7/13/2026 – Exelixis had its price target raised by Wells Fargo & Company from $40.00 to $49.00. They now have an “equal weight” rating on the stock.
• 7/8/2026 – Exelixis was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 7/7/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $43.00 to $46.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Exelixis had its price target raised by Truist Financial Corporation from $54.00 to $56.00. They now have a “hold” rating on the stock.
• 7/2/2026 – Exelixis had its “buy” rating reaffirmed by UBS Group AG.
• 7/2/2026 – Exelixis had its price target raised by UBS Group AG from $43.00 to $52.00. They now have a “neutral” rating on the stock.
• 7/2/2026 – Exelixis had its “buy” rating reaffirmed by HC Wainwright. They now have a $56.00 price target on the stock.
• 6/25/2026 – Exelixis was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $54.00 price target on the stock, up from $51.00.
• 6/24/2026 – Exelixis had its price target raised by Citizens Jmp from $50.00 to $55.00. They now have a “market outperform” rating on the stock.
• 6/22/2026 – Exelixis had its “positive” rating reaffirmed by Morgan Stanley.
• 5/19/2026 – Exelixis had its “buy (b)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Exelixis

In other news, EVP Dana Aftab sold 43,451 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president directly owned 594,741 shares in the company, valued at approximately $29,945,209.35. This represents a 6.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George Poste sold 60,000 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $45.71, for a total transaction of $2,742,600.00. Following the completion of the transaction, the director directly owned 118,832 shares of the company’s stock, valued at approximately $5,431,810.72. The trade was a 33.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 219,170 shares of company stock valued at $10,620,641 over the last ninety days. Corporate insiders own 2.60% of the company’s stock.

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.